Ken Frazier's final appearance on Merck & Co's financial results call as chief executive was a muted affair, as the company reported lower-than-expected revenues dragged down as the pan
Emergent BioSolutions' difficult month has been made worse by an FDA report into its facility in Baltimore, which has been blamed for the wastage of millions of doses of Johnson & Johns
